[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1730
1. Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol; 2008 Feb;21(2):115-24
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
  • Herein, we investigated the role of the platelet-derived growth factor pathway in the development of ovarian clear-cell adenocarcinoma, a highly chemoresistant form of ovarian cancer.
  • Immunohistochemical expression of platelet-derived growth factor receptor-alpha and receptor-beta, platelet-derived growth factor A-chain and B-chain was examined in 31 cases of clear-cell adenocarcinoma and 56 coexisting putative precursor lesions: 17 non-atypical and 19 atypical endometrioses, and 10 non-atypical and 10 atypical clear-cell adenofibroma components.
  • The frequencies of positivity for platelet-derived growth factor receptor-alpha and receptor-beta, and platelet-derived growth factor A-chain increased in accordance with higher cytologic atypia in the putative precursors: 71, 47, and 59% in the 17 non-atypical endometrioses, 84, 73, and 84% in the 19 atypical endometrioses, 0% each in the 10 non-atypical clear-cell adenofibromas, 100, 90, and 90% in the 10 atypical clear-cell adenofibromas, and 97, 97, and 100% in the 31 clear-cell adenocarcinomas, respectively.
  • Positivity for platelet-derived growth factor B-chain increased in accordance with increased atypia in clear-cell adenofibroma: 0% in non-atypical clear-cell adenofibromas, 30% in atypical clear-cell adenofibromas, and 60% in coexisting carcinomas.
  • However, in contrast, positivity for platelet-derived growth factor B-chain decreased in accordance with increased atypia in endometriosis coexisting with clear-cell adenocarcinomas: 35% in non-atypical endometrioses, 11% in atypical endometrioses, and 5% in coexisting carcinomas.
  • These results indicate activation of the platelet-derived growth factor pathway in ovarian clear-cell adenocarcinomas and suggest biological differences between carcinomas that arise in association with clear-cell adenofibroma vs endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenofibroma / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. Platelet-Derived Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084257.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


2. Kim L, Liao J, Zhang M, Talamonti M, Bentrem D, Rao S, Yang GY: Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol; 2008 Sep;21(9):1075-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta.
  • Clear cell carcinoma as a variant of ductal carcinoma of the pancreas is not well recognized.
  • Hepatocyte nuclear factor-1beta as a transcription factor has been identified as a specific biomarker of clear cell tumor of the female genital tract.
  • The aim of this study was to systematically analyze clear cell carcinoma of the pancreas and its unique biomarker hepatocyte nuclear factor-1beta.
  • A total of 84 pancreatic adenocarcinomas were analyzed pathologically and with an immunohistochemical approach with hepatocyte nuclear factor-1beta antibody.
  • The identified clear cell carcinomas were further studied by PAS, DPAS, and mucicarmine stains.
  • Of them, 20 (24%) pancreatic adenocarcinomas were identified with clear cell features, including 12 clear cell carcinomas and 8 ductal adenocarcinomas with clear cell component (defined as less than 75% of tumor with clear cells).
  • Cytologically, the clear cell carcinomas exhibited clear cytoplasm with centrally located, atypical nuclei.
  • PAS, DPAS, and mucicarmine stains confirmed that the clear cytoplasm was not due to accumulation of glycogen or mucin.
  • The results of immunostaining showed that hepatocyte nuclear factor-1beta is overexpressed in all clear cell carcinomas and in the clear cell components of eight ductal carcinomas with clear cell features.
  • In contrast, in usual ductal adenocarcinoma, hepatocyte nuclear factor-1beta exhibited overall weak or focally moderate staining; only eight cases were strongly positive (15%) of which 38% were high grade and 63% were moderate grade.
  • However, when included with the strong staining cases in mixed and clear cell carcinoma, this group regardless of morphology appeared to correlate with worse survival compared to the group with weak hepatocyte nuclear factor-1beta staining across morphologies (P<0.01).
  • Thus, clear cell carcinoma of the pancreas is not an uncommon variant of pancreatic ductal adenocarcinoma.
  • Hepatocyte nuclear factor-1beta is a useful marker to identify these clear cell carcinomas, and its overexpression may aid in stratifying survival rate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Hepatocyte Nuclear Factor 1-beta / analysis. Pancreatic Neoplasms / chemistry. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Immunohistochemistry. Neoplasm Staging. Periodic Acid-Schiff Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536653.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


3. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • They showed clear cytoplasm positive for periodic acid-Schiff stain, hobnail cells, and occasional hyaline globules.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


5. Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC: Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol; 2007 Jan;38(1):134-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.
  • Previously, we reported that ABCF2 protein expression is higher in clear cell than serous histotype of ovarian adenocarcinomas and that its expression correlates with chemoresponse in patients with clear cell ovarian cancer.
  • In this study, we examined ABCF2 protein expression in mucinous, endometrioid, and poorly differentiated type of ovarian adenocarcinomas.
  • In addition, ABCF2 expression was evaluated in clear cell adenocarcinomas derived from different organs.
  • A total of 335 epithelial ovarian cancers, 23 clear cell adenocarcinomas of uterine corpus, and 34 clear cell adenocarcinomas of kidney were included in this study.
  • The results showed that cytoplasmic ABCF2 expression was significantly higher in clear cell-type ovarian cancer specimens compared with other types (P < .0001).
  • There was a close relationship between nuclear ABCF2 expression levels and age of patients with clear cell ovarian cancer.
  • Multivariate logistic regression model also demonstrated that cytoplasmic ABCF2 expression was associated with clear cell histology (odds ratio, 5.557; 95% confidence interval, 2.694-11.462; P < .0001).
  • In addition, both clear cell adenocarcinomas of the ovary and the uterine corpus showed significantly higher levels of ABCF2 expression, compared with those of the clear cell adenocarcinoma of the kidney (P < .0001).
  • These data suggest that ABCF2 protein may be a candidate marker for clear cell adenocarcinomas of the ovary and the uterine corpus and may be important for the pathogenesis of these diseases.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Logistic Models. Middle Aged. Multivariate Analysis. Odds Ratio

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996567.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCF2 protein, human
  •  go-up   go-down


6. Ohishi Y, Kaku T, Kaneki E, Wake N, Tsuneyoshi M: Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study. Gynecol Oncol; 2007 May;105(2):548-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
  • BACKGROUND: Cases of malignant ovarian tumor composed of müllerian-type epithelial tumor and malignant germ cell tumor are extremely rare.
  • CASE: We herein report the case of a 34-year-old woman with an ovarian tumor which was composed of endometrioid adenocarcinoma (EAC), clear cell adenocarcinoma (CCC), squamous cell carcinoma, yolk sac tumor (YST) and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation.
  • Even after systemic chemotherapy, this intriguing tumor recurred again and again, which is in contrast to pure germ cell tumor which is known to be sensitive to chemotherapy.
  • Correct diagnosis of this complex and aggressive tumor is paramount.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / pathology. Endodermal Sinus Tumor / pathology. Female. Humans. Neuroectodermal Tumors / pathology. Rhabdomyosarcoma / pathology. Teratoma / pathology


7. Kuroda N, Shiotsu T, Ohara M, Hirouchi T, Mizuno K, Miyazaki E: Female urethral adenocarcinoma with a heterogeneous phenotype. APMIS; 2006 Apr;114(4):314-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female urethral adenocarcinoma with a heterogeneous phenotype.
  • We here report a very rare case of female urethral adenocarcinoma.
  • Cystoscopy showed a urethral tumor and the biopsy material showed adenocarcinoma.
  • Histologically, patterns of columnar/mucinous adenocarcinoma, clear cell adenocarcinoma and papillary/micropapillary carcinoma were observed, but there was no evidence of a cribriform pattern.
  • We suggest that female urethral adenocarcinoma with a histologically and immunohistochemically heterogeneous phenotype may originate from cells within urethral or paraurethral tissue, such as urethritis glandularis or intestinal metaplastic epithelium and Mullerian tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689832.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


8. Sung MT, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, Wang M, Tan PH, Cheng L: Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res; 2008 Apr 1;14(7):1947-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
  • PURPOSE: Clear cell adenocarcinoma in the urinary tract is a rare entity with an appearance resembling its counterpart in the female genital tract.
  • EXPERIMENTAL DESIGN: We integrated molecular genetic evaluation by fluorescence in situ hybridization and X-chromosome inactivation with conventional morphologic and immunohistochemical analyses in 12 patients with clear cell adenocarcinomas in the urinary tract.
  • RESULTS: Concurrent urothelial carcinoma or urothelial carcinoma in situ was present in six cases (50%) and foci of cystitis glandularis were observed in four cases (33%).
  • In UroVysion fluorescence in situ hybridization assays, all tumors displayed chromosomal alterations similar to those commonly found in urothelial carcinoma.
  • Identical patterns of nonrandom X-chromosome inactivation in concurrent clear cell adenocarcinoma and urothelial neoplasia were identified in two informative female cases.
  • CONCLUSIONS: Our findings support an urothelial origin for most clear cell adenocarcinomas of the urinary tract, despite their morphologic resemblance to certain Müllerian-derived tumors of the female genital tract.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Biomarkers, Tumor / analysis. Urologic Neoplasms / genetics. Urologic Neoplasms / metabolism. Urothelium / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. X Chromosome Inactivation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381932.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Sun K, Huan Y, Unger PD: Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med; 2008 Sep;132(9):1417-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
  • CONTEXT: Clear cell carcinoma of the urinary bladder/ urethra is a rare tumor histologically resembling the neoplasms in the female genital tract.
  • Adequate characterization of this tumor has been hampered by its rarity. alpha-Methylacyl-CoA racemase (AMACR)/P504S has been reported to be positive in prostatic adenocarcinoma, papillary renal cell carcinoma, and gastrointestinal neoplasmas; however, it has never been studied in clear cell carcinoma of the lower urinary tract.
  • OBJECTIVE: To investigate the immunohistochemical staining profile in 4 primary clear cell carcinomas of the urinary tract, including P504S, which has not been previously evaluated in these tumors.
  • DESIGN: Four cases of clear cell adenocarcinoma were retrieved from our archives: 2 cases from the urinary bladder (one each from a man and a woman) and 2 cases from the urethra (both from women, 1 in a diverticulum).
  • RESULTS: We found that clear cell carcinomas had a distinct immunoreactive profile: strongly positive for P504S, K903, and CK7, and negative for p63.
  • CONCLUSION: The immunohistochemical profile of clear cell carcinomas shares some similarity to conventional urothelial carcinoma; however, it deviates from those tumors in being positive for P504S and negative for p63.
  • This staining profile may suggest a nonurothelial origin for these tumors, may serve as a useful tool in the differential diagnosis of this tumor, and may reflect its etiology.
  • Because similar expression of P504S is also seen in nephrogenic adenomas, this marker should not be used to differentiate nephrogenic adenomas from clear cell adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Racemases and Epimerases / biosynthesis. Urethral Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788852.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CKAP4 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


10. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O: Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol; 2007 Jul;38(7):1074-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.
  • Recent studies have noted specific expression of hepatocyte nuclear factor (HNF) 1beta in ovarian clear-cell adenocarcinoma (CCA).
  • We examined HNF-1beta expression immunohistochemically in 186 ovarian carcinomas, including 40 CCAs; 33 endometrial carcinomas, including 5 CCAs; 22 endometria at different stages of the menstrual cycle (5 in the proliferative, 12 in the secretory, and 5 in the menstrual phases); and 7 gestational endometria.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Hepatocyte Nuclear Factor 1-beta / metabolism. Ovarian Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442376.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


11. Herawi M, Drew PA, Pan CC, Epstein JI: Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum Pathol; 2010 Apr;41(4):594-601
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.
  • Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell adenocarcinoma).
  • Twelve classic clear cell adenocarcinomas of the bladder and urethra and 7 nephrogenic adenoma-like clear cell adenocarcinomas were compared to 10 nephrogenic adenomas.
  • Classic clear cell adenocarcinomas and nephrogenic adenoma-like clear cell adenocarcinomas comprised 4 men and 15 women.
  • The following features were seen in classic clear cell adenocarcinomas: nephrogenic adenoma-like clear cell adenocarcinomas: predominantly solid pattern (7/12:0/7), marked nuclear pleomorphism (7/12:1/7), prominent nucleoli (5/12:1/7), clear cytoplasm in 50% or greater of tumor (7/12:0/7), and necrosis (8/12:3/7), although the necrosis in nephrogenic adenoma-like clear cell adenocarcinomas was often focal and intraluminal.
  • Both patterns of clear cell adenocarcinomas showed prominent hobnail features, although more pronounced in nephrogenic adenoma-like clear cell adenocarcinomas.
  • Muscularis propria invasion was seen in 5 of 9 classic clear cell adenocarcinomas and 6 of 6 nephrogenic adenoma-like clear cell adenocarcinomas, where evaluable.
  • Classic clear cell adenocarcinoma was associated with urothelial carcinoma (n = 2) and endometriosis (n = 1).
  • The Ki-67 rate in clear cell adenocarcinomas ranged from 10% to 80% compared with 0% to 5% in nephrogenic adenoma.
  • The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and alpha-methylacyl coenzyme-A racemase.
  • PAX2 expression was more frequent in nephrogenic adenoma (89%) compared to both patterns of clear cell adenocarcinoma (29%-32%).
  • The key features discriminating between nephrogenic adenoma-like clear cell adenocarcinoma and nephrogenic adenoma include occasional clear cells, more prominent pleomorphism especially hyperchromatic enlarged nuclei, and extensive muscular invasion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma / diagnosis. Urethral Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20060152.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol; 2006 Apr;101(1):71-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN expression in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary.
  • METHODS: Totally, 40 clear cell adenocarcinomas were included in this study.
  • RESULTS: Of 40 clear cell adenocarcinomas, 15 (37.5%) lost all PTEN immunoreactivity.
  • Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases.
  • CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290000.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


13. Kamai T, Tomosugi N, Abe H, Yoshida K: Protein profiling of tumor tissues by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between localized and metastatic renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of tumor tissues by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between localized and metastatic renal cell carcinoma.
  • : e16098 Background: We previously reported that mRNA of interferon-alpha receptor type 2 (IFNAR2) was upregulated in metastatic and IFN-a resistant renal cell carcinoma (RCC) in comparison to localized RCC or metastatic tumors with good response to IFN-a (BMC Cancer, 2007).
  • Then we selected representative five IFNAR2 upregulated clear cell carcinomas cases with metastatic tumor, five IFNAR2 upregulated metastatic sarcomatoid carcinomas, and five normal expression clear cell carcinomas with localized tumor.
  • Furthermore, the heat map discriminated metastatic sarcomatoid carcinomas from metastatic clear cell carcinomas with a sensitivity of 100% and a specificity of 80%.
  • Our findings may reflect different molecular mechanism between localized and metastatic carcinomas, and the different response to immunotherapy with IFN-α.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963090.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nagao S, Oishi R, Iwasa N, Shimizu M, Hasegawa K, Goto T, Fujiwara K: A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma.
  • : e16549 Background: This is a feasibility study for a future trial to assess the feasibility of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin and IP paclitaxel (TCipTip therapy) in patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • METHODS: The patients eligible for this study had histologically confirmed, stage IC-IV epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • The patients included 7 epithelial ovarian carcinoma (stage IC, 2; stage IIIC, 5), 2 stage IIIC primary peritoneal carcinoma, and 1 stage IIA fallopian tube carcinoma.
  • There were 7 serous adenocarcinoma, 2 endometrioid adenocarcinoma, 1 clear cell adenocarcinoma.
  • CONCLUSIONS: TCipTip therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gibbons DL, Lin W, Creighton C, Zhang S, Lozano G, Kurie J: Use of a murine model of NSCLC to evaluate the role of the microRNA-200 family in regulating EMT and metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):11006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11006 Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, primarily due to metastatic disease.
  • Unfortunately, we lack a clear understanding of the molecular and cellular basis for lung cancer metastasis, partly because the experimental study is hampered by lack of good models.
  • METHODS/RESULTS: To address this deficiency we have developed an experimental murine model of metastatic NSCLC using cell lines derived from a genetic mouse model of human lung adenocarcinoma that develops metastatic disease owing to the expression of K-ras<sup>G12D</sup> and p53<sup>R172H</sup>.
  • An expression signature derived from the spontaneous metastatic tumors in these animals is prognostic when applied to a large series of early-stage patient tumors, illustrating that the model recapitulates features of the human disease.
  • Forced expression of the miR-200 family produced a more epithelial cell phenotype and associated changes in the ability of the cancer cells to respond to EMT-inducing stimuli such as TGFβ.
  • We believe this to be a mechanism whereby changes in the tumor microenvironment influence tumor cell state and ability to undergo metastasis.
  • Using this experimental animal model has revealed a role for EMT in the pathogenesis of the disease and the microRNA-200 family as regulators of the cellular switch.
  • This work should provide new insights into the cell biology of tumor progression and metastasis, while generating new potential targets for therapy of metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964037.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ravaud A, Oudard S, Gravis-Mescam G, Sevin E, Zanetta S, Théodore C, de Fromont M, Mahier-Aït Oukhatar C, Chêne G, Escudier B: First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):5146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP).
  • : 5146 Background: Sunitinib (Su) has been approved in metastatic clear cell carcinoma due to high objective response rates (ORR) and a prolonged progression-free survival (PFS).
  • Type I and II papillary RCC pts have a poor prognosis, with limited effective agents.
  • SUPAP is exploring type I and II PRCC separately with an identical design.
  • Main eligibility criteria included type I or II PRCC confirmed by central pathological review, PS 0-1, measurable disease, first line of treatment.
  • RESULTS: From 10/07 to 11/08, 5 pts with type I and 23 pts with II PRCC were included.
  • In type II PRCC, 1/23 pts had a partial response (PR), 13/23 pts had a stable disease (SD) with 4 pts with a SD ≥ 12 weeks, 5/23 pts were progressive, 3/23 pts were too early for evaluation and 1/23 was not evaluable.
  • In type I PRCC, none had a partial response (PR), 3/5 pts had stable disease (SD) and 2/5 pts were too early for evaluation.
  • CONCLUSIONS: Although some activity has been observed, response rate was lower than in clear cell tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964444.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Keegan KA, Hellenthal NJ, Chamie K, Koppie TM: Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage? J Clin Oncol; 2009 May 20;27(15_suppl):5089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage?
  • : 5089 Background: The impact of renal cell carcinoma histopathology (RCC) on survival has been conflicting and limited to retrospective institutional studies.
  • Patients were stratified based on histopathologic diagnosis (clear cell, papillary, chromophobe, sarcomatoid, and collecting duct) and pathologic stage.
  • Specifically, patients with papillary and chromophobe variants had lower stage disease at the time of surgery and had improved survival compared to clear cell subtypes, (HR: 0.50; 95% CI, 0.42-0.60 and HR: 0.31; 95% CI, 0.22-0.44, respectively).
  • On the other hand, patients with sarcomatoid disease were more likely to present with high stage disease and invariably had worse survival compared to clear cell carcinoma (HR: 8.74; 95%, CI 7.70-9.91).
  • Patients with sarcomatoid RCC, even those presenting with low-stage disease, have poor survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964288.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Johnson FM, Tang X, Tran H, Saigal B, Erasmus J, Kurie J, Hwang L, Oh Y, Lippman S, Stewart DJ: Phase II study of dasatinib in non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of dasatinib in non-small cell lung cancer (NSCLC).
  • Of the 16 patients evaluable for response: 1 had a partial response (PR) with no evidence of recurrence for at least 18 months (male smoker with adenocarcinoma and KRAS mutation); 6 patients had stable disease (SD) which includes 3 patients with prolonged stable disease for 4, 6, and 18 months; 9 had progressive disease (PD).
  • There is currently no clear association between EGFR and KRAS mutational analysis and response, although the sample number is small.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mendivil A, Vogel TJ, Bae-Jump VL, Gehrig PA: A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer.
  • However, the effect that a prior breast cancer diagnosis may have on women with a new endometrial cancer diagnosis is less well described.
  • The goal of our study was to determine the effect that a prior history of breast cancer would have on the outcome for women with type II uterine cancer.
  • All women treated for uterine carcinoma between 1994 and 2007 were identified and we identified women with either uterine serous (UPSC) or clear cell carcinoma (UCCC) as the study group.
  • The patients were then divided between those with and those without a prior breast cancer diagnosis.
  • Patient demographics, cancer histologies, and stage of disease data were collected.
  • RESULTS: Approximately 1,083 patients were treated for uterine carcinoma during the study period of which 74 had pre-existing breast carcinoma (6.9%).
  • One hundred and fifty women had USC and/or UCCC (13.8%) of whom 23 also had pre-existing breast carcinoma (13.3%).
  • The women with breast cancer where older at the time of their uterine cancer diagnosis (77 y.o.) compared to those without breast cancer (68 y.o.
  • While having two primary malignancies can be devastating, our study indicated that women who developed a type II uterine cancer and also had a history of a prior breast cancer had the same outcomes as those women without a prior cancer diagnosis.
  • This finding may help to allay patients' fears about developing another malignancy and its impact on their prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962613.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Litvinova TM, Kosenko IA: [Treatment outcomes in patients with unfavorable histologic type of endometrial carcinoma]. Vopr Onkol; 2006;52(1):89-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcomes in patients with unfavorable histologic type of endometrial carcinoma].
  • Five-year overall and recurrence-free survival was evaluated in 84 stage I endometrial cancer patients with such histological patterns as poorly differentiated endometrioid adenocarcinoma, clear-cell carcinoma, serous papillary cancer, poorly differentiated cancer and mixed-type carcinoma.
  • Overall 5-year survival in the whole group was 60.1 +/- 5.9% while recurrence-free survival--52.1 +/- 5.9%, those rates for poorly differentiated endometrioid adenocarcinoma being 50.8 +/- 7.3% and 41.9 +/- 7.4%, respectively.
  • Our data suggest that combination therapy is ineffective in the management of stage I endometrial carcinoma when histotype of tumor is unfavorable (overall 5-year survival - 56.51 +/- 7.8%; recurrence-free survival--49.7 +/- 7.9%).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715712.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


21. Tibau A 1st, Ojeda B 1st, Nadal R 1st, Pérez Altozano J 1st, Boguña I 1st, Artigas V 1st, Gallardo A 1st, Pérez C 1st, Lopez J 1st, Barnadas A 1st: The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma.
  • Tumors were classified: 70 (55%) serous, 24 (19%) poorly differentiated, 14 (11%) endometrioid and 19 (15%) clear cell carcinoma.
  • Residual disease after initial surgery: 52 (41%) optimal <2cm and 39 (31%) suboptimal.
  • Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960780.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kösem M, Sengül E: Clear cell adenocarcinoma of the urinary bladder. Scand J Urol Nephrol; 2005;39(1):89-92
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the urinary bladder.
  • Clear cell adenocarcinoma of the lower urinary tract, and particularly of the bladder, is a rare neoplasm and its histogenesis remains obscure.
  • The authors report the clinical and pathologic findings of a 55-year-old male with clear cell carcinoma of the bladder.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Urinary Bladder / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764280.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 15
  •  go-up   go-down


23. Adams B, Sawhney R, Sheil A, Chaudhary UB: A rare case of clear cell adenocarcinoma of the bladder with unique pathological features. Am J Med Sci; 2007 Jan;333(1):63-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of clear cell adenocarcinoma of the bladder with unique pathological features.
  • Clear cell adenocarcinomas of the urinary bladder are rare tumors with an unknown histogenesis.
  • Since these tumors appear histologically similar to clear cell tumors of the female genital tract, a mullerian histogenesis has been proposed.
  • Several publications have examined the immunohistochemical properties of clear cell adenocarcinomas to improve understanding of the cause and pathogenesis of this tumor.
  • While specific criteria for a diagnosis of clear cell adenocarcinoma have not been defined, there are consistent staining patterns suggested for characterization.
  • We present an important case of clear cell adenocarcinoma of the bladder with a unique staining pattern.
  • We review the literature and discuss the differential diagnosis and various theories concerning the origin of this rare tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220697.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


24. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Eight of 11 (77%) TAs with clear cell change had focal to extensive high-grade dysplasia.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • PAS/PAS-diastase stains showed minimal PAS(+) material in the clear cells.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • In 3 of the 11 lesions, the background TA showed at least focal MUC5 immunoreactivity, their associated clear cell area had decreased MUC5 labeling in all 3 cases.
  • No immunoreactivity to MUC6 was observed in the background TAs and clear cells in all cases.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • Awareness of them and their immunoprofile allows distinction from clear cell lesions from other sites.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


25. Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, Kigawa J, Sugiyama T, Yaegashi N, Aoki D: Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer; 2010 Feb;20(2):220-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
  • Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types.
  • Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134266.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIG2 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Yabushita H, Kanyama K, Sekiya R, Noguchi M, Wakatsuki A: Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent. Int J Clin Oncol; 2008 Dec;13(6):552-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent.
  • This report describes the case of the youngest Japanese person to be diagnosed with endocervical clearcell adenocarcinoma.
  • The cytological finding of the uterine cervix was positive for malignancy, and the histological diagnosis by punch biopsy was clear-cell adenocarcinoma of the uterine cervix.
  • The pathological diagnosis was clear-cell adenocarcinoma of the cervix (PT1b1NR0M0).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093185.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Kobayashi M, Hattori M, Miyamoto T, Kakinuma H, Watanabe J, Iwabuchi K, Nishimura Y, Jobo T, Kuramoto H: Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report. Acta Cytol; 2007 Nov-Dec;51(6):916-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report.
  • BACKGROUND: Clear cell adenocarcinoma (CCA) of the minor salivary gland accounts for < 1% of all tumors of the salivary gland.
  • CASE: A 32-year-old woman with a history of papillary carcinoma of the thyroid 1 year earlier complained of pain on the left side of the neck.
  • Imprint cytology of the tumor revealed cohesive tumor cells of uniform size containing an abundant clear cytoplasm and round nuclei with extra but fine granular chromatin and conspicuous nucleoli.
  • Histopathologic analysis confirmed the trabecular or nest-like arrangement of the cells with the clear cytoplasm and BMS substance surrounded by tumor cells, which were positive for laminin and AE1 immunohistochemically.
  • CONCLUSION: Although CCA of the palate is extremely rare, an accurate cytologic diagnosis can be made if the characteristic findings of CCA, including BMS, are imaged.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Basement Membrane / pathology. Palatal Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Cytodiagnosis / methods. Disease-Free Survival. Female. Humans. Laminin / metabolism. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077986.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


28. Uddin Z, Yaqoob N, Kayani N, Hasan SH: Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis. J Pak Med Assoc; 2007 Jul;57(7):373-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis.
  • Histological picture showed clear cell carcinoma with areas of mucinous cystadenoma and endometriosis.
  • Clear cell carcinoma is known to be associated with endometriosis.
  • To the best of author's knowledge, it's association with mucinous cystadenoma has been described only once in the literature, where clear cell carcinoma was shown to be associated with mucinous cystadenoma without any evidence of endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Cystadenoma, Mucinous / complications. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867264.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


29. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Both are cell lineage restricted transcription factors expressed in normal and neoplastic tissues of related origin, including renal tubular cells in both fetal and adult kidneys.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


30. Suzuki N, Higashiguchi A, Hasegawa Y, Matsumoto H, Oie S, Orikawa K, Ezawa S, Susumu N, Miyashita K, Aoki D: Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell; 2005 Sep;18(3):147-55
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells.
  • Among various types of surface epithelial ovarian carcinoma, clear cell adenocarcinoma often has a particularly poor prognosis even when diagnosed in stage I.
  • The present study was conducted using cell lines derived from ovarian clear cell adenocarcinoma in order to identify genes associated with the acquisition of malignant potential by this type of cancer.
  • Two cell lines derived from ovarian clear cell adenocarcinoma (RMG-I and RMG-V), with different levels of invasive potential in an invasion assay, were used.
  • Primers were established using these base sequences and the level of expression in each cancer cell line was determined by real-time PCR.
  • It was also detected by a microarray analysis as one of the molecules showing a different level of expression between the two cell lines.
  • Then the pattern of integrin a3 expression was investigated using immunocytochemical staining, and was found to differ between the two cell lines.
  • The findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Gene Expression Regulation, Neoplastic. Integrin alpha3 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022147.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Integrin alpha3
  •  go-up   go-down


31. Novák P, Németh I, Hamar S, Tiszlavicz L, Szalai L, Sonkodi I, Nagy K: [Clear cell adenocarcinoma of the tongue. Coincidence or distant metastasis?]. Fogorv Sz; 2009 Oct;102(5):183-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell adenocarcinoma of the tongue. Coincidence or distant metastasis?].
  • [Transliterated title] Világossejtes adenocarcinoma a nyelvben. Koincidencia vagy attét?
  • Malignant tumors of the salivary glands are rare, they account for less than 0.5% of all malignancies and for 5% of cancers of maxillofacial regions.
  • Clear cell adenocarcinoma represents 1% of malignant tumors of the salivary glands.
  • Her past medical history included right nephrectomy of renal cell carcinoma, seven years before the tongue tumor.
  • The initial orofacial clinical examination suspected lipoma, neurinoma or distant metastasis of the renal cell carcinoma.
  • The histomorphological analysis of the resected tongue tumor showed similar clear cell adenocarcinoma mimicking the phenotype of renal cell carcinoma but detailed immunohistochemical analysis proved the primary origin of tongue indicating second primary metachronous malignant tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Neoplasms, Second Primary. Tongue Neoplasms
  • [MeSH-minor] Carcinoma, Renal Cell / surgery. Female. Humans. Kidney Neoplasms / surgery. Middle Aged. Nephrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20000197.001).
  • [ISSN] 0015-5314
  • [Journal-full-title] Fogorvosi szemle
  • [ISO-abbreviation] Fogorv Sz
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


32. Guo YF, Liu AJ, Wang XL, Wu XZ, Song L, Liu HT: [Human papillomavirus detection in clear cell carcinoma of the cervix]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr;23(2):82-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomavirus detection in clear cell carcinoma of the cervix].
  • OBJECTIVE: To investigate the infection of the high risk human papillomavirus (HPV) in the specimen of the clear cell carcinoma of the cervix.
  • METHODS: We extracted the nucleic acids in the formalin-fixed and paraffin-embedded specimens from a 37-year-old patient with clear cell carcinoma of the cervix and detected the HPV genotype with the nested PCR.
  • CONCLUSION: The HPV detection with the nested PCR was available for identification of the HPV genotype(s) in the paraffin-embedded specimens of clear cell carcinoma of the cervix (CCCC) with a high accuracy and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / virology. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104741.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


33. Kitada M, Ozawa K, Sato K, Hayashi S, Miyokawa N, Sasajima T: Clear cell carcinoma of the lung. Gen Thorac Cardiovasc Surg; 2010 Feb;58(2):87-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the lung.
  • We present here in the case of a patient who underwent resection of clear cell carcinoma of the lung, a rare histological type.
  • A screening test of the 71-year-old woman revealed a 2.0-cm lesion in S4 of the right lung with a diagnosis of bronchioloalveolar carcinoma before resection.
  • The histopathological examination showed clear, slightly acidophilic tumor cells rich in fine granular components proliferating in an alveolar fashion.
  • Immunostaining was diagnostically useful, distinguishing clear cell carcinoma from lung metastasis of renal clear cell carcinoma or clear cell squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Biopsy. Cell Differentiation. Cell Proliferation. Diagnostic Errors. Female. Humans. Immunohistochemistry. Lymph Node Excision. Neoplasm Staging. Predictive Value of Tests. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20155345.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Vrdoljak-Mozetic D, Stanković T, Krasević M, Versa-Ostojić D, Stemberger-Papić S, Rupcić S: Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology; 2006 Dec;17(6):390-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative cytology of clear cell carcinoma of the ovary.
  • OBJECTIVE: To describe the cytomorphology of clear cell carcinoma (CCC) of the ovary in intraoperative samples of peritoneal fluid, imprint and scraping samples of the tumour tissue.
  • RESULTS: In 33.3% of peritoneal fluid samples and 92.9% of imprint and scraping cytological samples, besides variable clear cell cellular morphology, one or both distinct cytological characteristics were observed: eosinophilic, hyaline, extracellular, globular substance with or without formation of a 'raspberry' body and an eosinophilic, intracytoplasmic inclusions.
  • CONCLUSION: Using cytological analysis of imprint and scraping samples of ovarian tumours it is possible to make a precise intraoperative cytological diagnosis in most cases of CCC of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168923.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Goto K, Takeuchi Y, Yakihara A, Kotsuji F: Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecol Oncol; 2005 Jun;97(3):976-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status.
  • BACKGROUND: A multiple primary invasive carcinoma of the cervix is a rare condition and is seldom composed of squamous cell carcinoma and clear cell adenocarcinoma.
  • Preoperative pathological and imaging studies demonstrated the squamous cell carcinoma of the exocervix alone.
  • Radical hysterectomy was performed on the diagnosis of stage 1B cervical cancer.
  • Histological examination of the specimen manifested a coexisting invasive clear cell adenocarcinoma in the endocervix.
  • Human papillomavirus (HPV) 18 was detected in the squamous cell carcinoma; however, no HPV was detected in the clear cell adenocarcinoma.
  • CONCLUSION: This finding suggests that there was an obvious difference in association of HPV with the two neoplasms.
  • [MeSH-major] Adenocarcinoma, Clear Cell / virology. Carcinoma, Squamous Cell / virology. Neoplasms, Multiple Primary / virology. Papillomaviridae. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896829.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Hao LS, Zhu X, Zhao LH, Qian K, Zhou Y, Bu J, Wu XT: Clear cell adenocarcinoma of colorectum: a case report and review of the literature. Acta Gastroenterol Belg; 2007 Apr-Jun;70(2):235-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of colorectum: a case report and review of the literature.
  • Primary clear cell adenocarcinoma of the colorectum is a rare neoplasm, which differs from ordinary carcinomas of the colorectum in morphological features, but shares some traits of clear cell carcinoma of other organs.
  • The tumor is usually composed of polygonal or oval cells with abundant granular and clear cytoplasm.
  • We report the first case of clear cell adenocarcinoma of the colorectum in China and review the related published cases.
  • By immunoperoxidase and histochemical staining, we clarified the clinicopathological characteristics, diagnosis and differential diagnoses, and pursued its potential pathogenesis.
  • In our case, necrosis, high mitotic activity and lymph node metastasis may suggest a highly malignant tumor and an advanced pathological stage.
  • Regardless of the stage and differentiation, surgical therapy and proper adjuvant chemotherapy are effective means to treat the clear cell adenocarcinoma of the colorectum.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Colectomy / methods. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Colonoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715642.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


37. Markopoulos C, Mantas D, Philipidis T, Kouskos E, Antonopoulou Z, Hatzinikolaou M, Gogas H: Glycogen-rich clear cell carcinoma of the breast. World J Surg Oncol; 2008;6:44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycogen-rich clear cell carcinoma of the breast.
  • BACKGROUND: Glycogen-rich carcinoma of the breast is a rare histological subtype of breast cancer, usually reported to have poor prognosis.
  • CASE PRESENTATION: We present the case of a 59-year-old woman who underwent a mastectomy for a 3.5 cm clinically palpable left breast carcinoma, originally diagnosed as fibroadenoma on a screening mammogram four years before presentation.
  • Diagnosis of clear cell carcinoma was based on certain histological characteristics of the tumour and immunohistochemical analysis (PAS staining, keratins AE1/AE3, EMA, cytokeratin 7, cytokeratin 20, melanosomes, vimentin, Chromogranin, Synaptophysin, S-100, SMA).
  • No lymph node metastasis was found and as the tumour was ER positive and PgR negative, patient was treated only with an aromatase inhibitor upfront and remains free of disease 48 months now since operation.
  • CONCLUSION: Glycogen-rich clear cell carcinoma of the breast is a rare tumor, its clinical behavior reported to be rather aggressive so far, might varies depending on special characteristics such as low grade and strongly positive ER expression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Breast Neoplasms / pathology. Glycogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Apr;31(4):793-800 [4350331.001]
  • [Cites] Yale J Biol Med. 1971 Feb-Apr;43(4-5):213-22 [5578741.001]
  • [Cites] Hum Pathol. 1975 May;6(3):384-90 [1132876.001]
  • [Cites] J Pathol Bacteriol. 1964 Jan;87:25-7 [14106350.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):904-11 [7611537.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):81-3 [1985082.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2003-9 [6271388.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1980 Mar-Apr;89(2 Pt 1):168-72 [7189393.001]
  • [Cites] Cancer. 1976 May;37(5):2355-8 [1260721.001]
  • [Cites] Arch Pathol Lab Med. 1977 Mar;101(3):140-4 [576578.001]
  • [Cites] Pathology. 1977 Oct;9(4):341-6 [593733.001]
  • [Cites] Am J Clin Pathol. 1980 Jan;73(1):31-5 [6243441.001]
  • (PMID = 18442419.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  • [Other-IDs] NLM/ PMC2386120
  •  go-up   go-down


38. Abascal Junquera JM, Cecchini Rosell L, Martos Calvo R, Salvador Lacambra C, Celma Doménech A, De Torres I, Morote Robles J: [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management]. Actas Urol Esp; 2007 Apr;31(4):411-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management].
  • [Transliterated title] Presentación de un nuevo caso de adenocarcinoma de células claras uretral y su manejo quirúrgico.
  • OBJECTIVE: To present a new case of a primary clear cell adenocarcinoma of the urethra and its surgical management.
  • MATERIAL AND METHODS: We describe the clinical, diagnosis, treatment and development of this kind of tumor.
  • CONCLUSIONS: It is an unusual type of cancer associated with poor prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Urethral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633929.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


39. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M: Clear cell carcinoma of the uterus. Tunis Med; 2010 Apr;88(4):230-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the uterus.
  • AIM: The aim of this study was to determine the characteristics and outcome of patients presenting with clear cell carcinoma (CCC) of the endometrium treated in a single institution.
  • Pathological features were studied in order to determine predictif factors of extrauterine disease extention and failure patterns.
  • The mean age at diagnosis was 64 years (50 to 84 yers).
  • CONCLUSION: Extrauterine extension is frequent at diagnosis and not correlated to classical risk factors observed in endometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446254.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


40. Ponniah I, SureshKumar P, Karunakaran K: Clear cell carcinoma of minor salivary gland--case report. Ann Acad Med Singapore; 2007 Oct;36(10):857-60
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of minor salivary gland--case report.
  • INTRODUCTION: Clear cell carcinoma is a rare low-grade carcinoma that almost exclusively occurs in the minor salivary glands.
  • TREATMENT AND OUTCOME: A preoperative diagnosis of primary clear cell carcinoma of salivary gland with focal surface epithelial dysplasia was rendered after thorough clinical examination to rule out renal origin.
  • The lesions were excised with wide surgical margins and 3 years into the postoperative period, the patient was disease-free.
  • CONCLUSION: We report a case of clear cell carcinoma of intra-oral minor salivary gland and draw comparisons with metastatic clear cell carcinoma of renal origin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987239.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


41. Nakazato T, Kanuma T, Tamura T, Faried LS, Aoki H, Minegishi T: Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):426-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer.
  • Clear cell adenocarcinoma of the ovary has a poor prognosis due to chemoresistance and early metastasis to the lymph nodes.
  • It also can result in endometriosis and is the second most frequent type of ovarian cancer in Japan.
  • Serous adenocarcinoma of the ovary is another common epithelial cancer tissue subtype in Japan, and it is highly sensitive to chemotherapy.
  • We used differential display to compare clear cell carcinoma and serous adenocarcinoma of the ovary.
  • We identified sperm protein 17 (SP17) as a candidate gene related to the chemoresistance of clear cell carcinoma.
  • Our results strongly suggest that SP17 plays a role in the resistance of clear cell carcinoma to chemotherapy without influencing their ability to proliferate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Antigens, Surface / genetics. Carrier Proteins / genetics. Drug Resistance, Neoplasm / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309563.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / RNA, Small Interfering; 0 / SPA17 protein, human
  •  go-up   go-down


42. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF: Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol; 2008 Sep;110(3):336-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
  • OBJECTIVE: The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary.
  • Advanced tumor stage at diagnosis (HR 13, 95% C.I.
  • Disease recurrence or death among optimally and completely cytoreduced patients was 31% and 59% for those with and without endometriosis respectively (P>0.05).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639330.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


43. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • The 5-year disease-specific survival probability for patients with a BRCA2 alteration is 87.5%, compared to only 40% for those patients without a BRCA2 alteration (p = 0.39).
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


44. Renaud MC, Plante M, Grégoire J, Roy M: Primitive clear cell carcinoma of the vagina treated conservatively. J Obstet Gynaecol Can; 2009 Jan;31(1):54-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive clear cell carcinoma of the vagina treated conservatively.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina is rare tumour that is usually treated aggressively.
  • We report a case of clear cell adenocarcinoma in which conservative treatment using new technology was successfully completed.
  • CASE: A 19-year-old woman with a biopsy proven clear cell adenocarcinoma of the vagina was referred to our clinic.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Fertility. Vaginal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208284.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


45. Cetin A, Bahat Z, Cilesiz P, Demirbağ N, Yavuz E: Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report. Eur J Gynaecol Oncol; 2007;28(3):241-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report.
  • BACKGROUND: Alpha-fetoprotein (AFP) is a useful tumor marker for germ cell tumors of the ovary and is valuable for both diagnosis and follow-up.
  • However, it is very rare for an epithelial ovarian carcinoma to secrete AFP.
  • CASE: We report a case of a 63-year-old woman with a ovarian clear cell carcinoma with serous component of less than 10%.
  • CONCLUSION: Ovarian clear cell type carcinomas rarely secrete only AFP and it might be the single marker that could be used in follow-up.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secretion. Biomarkers, Tumor / blood. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secretion. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2007;28(6):432. Cikesiz, P [corrected to Cilesiz, P]
  • (PMID = 17624099.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


46. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol; 2007 May;105(2):404-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
  • OBJECTIVE: Clear cell carcinoma of the ovary is an aggressive tumor characterized by relative chemoresistance and a poor prognosis.
  • The purpose of this study was to review our experience with recurrent clear cell carcinoma of the ovary to evaluate its responsiveness to systemic cytotoxic and hormonal agents.
  • METHODS: All patients diagnosed with clear cell carcinoma of the ovary seen at our institution between 1990 and 2002 were identified and their medical records reviewed.
  • 1) primary diagnosis of clear cell carcinoma of the ovary, 2) measurable recurrent disease, 3) treatment of recurrent disease with 1 or more systemic regimens, and 4) adequate clinical information.
  • RESULTS: Fifty-one patients treated for recurrent clear cell carcinoma were identified.
  • Among patients with platinum-sensitive disease (n=22 regimens), 2 patients (9%) had partial responses to retreatment with carboplatin plus paclitaxel, and 4 (18%) had stable disease.
  • Among patients with platinum-resistant disease (n=83 regimens), only 1 patient (1%) had a partial response - to gemcitabine - and 1 patient had stable disease in response to 2 different regimens-paclitaxel and gemcitabine.
  • CONCLUSION: Our findings suggest that recurrent clear cell carcinoma of the ovary is particularly chemoresistant.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292461.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


47. Okuda M, Huang CL, Haba R, Yokomise H: Clear cell carcinoma originating from ectopic thymus. Gen Thorac Cardiovasc Surg; 2009 May;57(5):269-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma originating from ectopic thymus.
  • Cancer of the mediastinum is known to be a relatively rare disease, and clear cell carcinoma in the mediastinum is especially rare.
  • Ectopic thymus is not uncommon, but clear cell carcinoma originating from ectopic thymus has never been reported.
  • We report a case of clear cell carcinoma originating from ectopic thymus in which there was a good response to steroid-supplemented chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Choristoma / pathology. Mediastinal Neoplasms / pathology. Thymus Gland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440827.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • Twenty-nine of 60 (48%) clear cell carcinomas showed a mucoid stroma, either focally (21 cases) or diffusely (8 cases).
  • The mucoid stroma in clear cell carcinomas was distinct from that in other surface epithelial tumors as follows: it showed a compact spherule-like appearance, commonly occupying the cores of small papillae.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • Among 40 clear cell carcinomas that had at least one type of stroma, 26 (65%) had both, either concomitantly or separately.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


49. Llarena Ibarguren R, García-Olaverri Rodríguez J, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metachronic testicular metastasis secondary to clear cell renal adenocarcinoma]. Arch Esp Urol; 2008 May;61(4):531-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronic testicular metastasis secondary to clear cell renal adenocarcinoma].
  • [Transliterated title] Metástasis testicular metacrónica secundaria a adenocarcinoma renal de células claras.
  • The pathology result was clear cell adenocarcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592774.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


50. Pujary K, Rangarajan S, Nayak DR, Balakrishnan R, Ramakrishnan V: Hyalinizing clear cell carcinoma of the base of tongue. Int J Oral Maxillofac Surg; 2008 Jan;37(1):93-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing clear cell carcinoma of the base of tongue.
  • Hyalinizing clear cell carcinoma is a rare, low-grade neoplasm of the minor salivary glands.
  • It is composed exclusively of epithelial cells with optically clear cytoplasm.
  • Once confirmed by biopsy, the hyalinizing clear cell carcinoma was resected via a transcervical approach.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822882.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


51. Lindahl B, Persson J, Ranstam J, Willén R: Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. Anticancer Res; 2010 Sep;30(9):3727-30
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
  • Uterine clear cell carcinoma (UCC) and uterine papillary serous carcinoma (UPSC) are rare entities that differ in clinical behavior from endometrial adenocarcinoma.
  • Compared with endometrioid adenocarcinoma, they more often metastasize early and more commonly in the upper abdomen including the omentum.
  • In stage Ia, 2/46 patients died of their disease and amongst all the stages, 30/109 patients died of their disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Cystadenocarcinoma, Serous / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944161.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S, Terakawa N: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1040-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
  • Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy.
  • We conducted the present study to find the gene that regulates cell proliferation of CCC and to elucidate whether it contributes to cisplatin (CDDP) resistance.
  • Complementary DNA microarray analysis revealed that the gene expression level of galectin-3 of CCC cell lines (KK, RMG-I, HAC-2) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF).
  • The present study showed that the expression of galectin-3 in CCC might contribute to its lower cell proliferation and lead to CDDP resistance.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Drug Resistance, Neoplasm / genetics. Galectin 3 / physiology. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis. Cell Line, Tumor. Cisplatin / therapeutic use. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Humans. Immunohistochemistry. RNA, Small Interfering / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433067.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Galectin 3; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Mazouzi A, Benjelloun H, Benchekroun N, Acharki A, Benider A: [Clear cell carcinoma of the parotid gland]. Ann Otolaryngol Chir Cervicofac; 2005 Jun;122(3):142-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell carcinoma of the parotid gland].
  • [Transliterated title] Carcinome à cellules claires de la glande parotide.
  • OBJECTIVES: Clear cell carcinomas of the parotid gland are hardly reported only fifty cases are known.
  • They are characterized by a proliferation of acinic epithelial cells and of clear myo epithelial cells.
  • The diagnosis was established by the parotid biopsy in 2 cases and after surgery in the third case.
  • It resulted in stabilization of the disease and a receding of 22 months for one patient and no trace of the second one because of a loss of the evolutionary pursuit.
  • CONCLUSION: With an in-depth analysis we can notice that clear cell carcinomas of the parotid gland are rare and mostly occur to old patients.
  • Radiation therapy linked to surgery seems to improve the local control of the disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142093.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Tan YT, Zhang X, Lin ZQ, Chen Q, Wang LJ, Zhang BZ: [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):120-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
  • OBJECTIVE: To explore the clinical diagnostic and therapeutic characteristics, prognostic factors of patients with primary clear cell carcinoma of the cervix.
  • METHODS: The clinical, pathologic and follow-up data of patients with primary clear cell carcinoma of the cervix treated in our hospital from Jan 2003 to Dec 2006 were collected and analyzed retrospectively.
  • RESULTS: Five patients with primary clear cell carcinoma of the cervix were treated (1 case stage I b1, 2 of stage I b2, 1 of stage IIa, 1 of stage IVa).
  • The primary symptom was mostly irregularly vaginal bleeding (3/5) and clinical type was predominantly (4/5) endophytic growth.
  • CONCLUSIONS: Primary clear cell carcinoma of the cervix may be unrelated to HPV infection.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. CA-125 Antigen / blood. Uterine Cervical Neoplasms / pathology


55. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • The tumor compressed the inferior vena cava (IVC), but it was not clear whether it invaded the vessel.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Gadducci A, Cosio S, Spirito N, Cionini L: Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res; 2010 Apr;30(4):1327-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the endometrium: a biological and clinical enigma.
  • Clear cell carcinoma accounts for only 1 to 5.5% of all endometrial carcinomas, and it is often associated with an aggressive clinical behavior and a poor outcome.
  • According to the FIGO Annual Report 2006, 5-year overall survival was 62.5% for patients with this histological type compared with 83.2% for those with endometrioid carcinoma of the endometrium.
  • In contrast to endometrioid carcinoma and uterine papillary serous carcinoma (UPSC), the molecular pathways involved in the development of clear cell carcinoma are still unclear.
  • Literature data on the pattern of failures and the optimal treatment modalities of the clear cell carcinoma are not well defined, largely because most papers have assessed clear cell carcinoma and UPSC together because of their rarity.
  • Patients with clear cell carcinoma often experience relapse in the pelvis, in para-aortic nodes and at distant sites, whereas they do not seem to have a high propensity to fail in the abdomen.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy with comprehensive surgical staging is the standard surgical treatment of patients with clear cell carcinoma of the endometrium, whereas pelvic irradiation, with or without brachytherapy and/or para-aortic irradiation, whole-abdomen irradiation, and chemotherapy have been widely employed as postoperative therapy.
  • An adequate molecular characterization of clear cell carcinoma of the endometrium is strongly warranted in order to identify new biological prognostic variables of the disease and to develop novel molecular targeted therapies.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530448.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 73
  •  go-up   go-down


57. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep; 2009 Aug;22(2):233-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
  • Among EOC, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology
  • [MeSH-minor] Cell Cycle Proteins / physiology. F-Box Proteins / physiology. Female. Genes, Tumor Suppressor. Hepatocyte Nuclear Factor 1-beta / physiology. Humans. Loss of Heterozygosity. Microsatellite Instability. Oxidative Stress. Protein Kinases / physiology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578761.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Number-of-references] 56
  •  go-up   go-down


58. Tan DS, Kaye S: Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol; 2007 Apr;60(4):355-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian clear cell adenocarcinoma: a continuing enigma.
  • Ovarian clear cell adenocarcinomas (OCCAs) account for <5% of all ovarian malignancies.
  • By contrast, early-stage clear cell ovarian cancer carries a relatively good prognosis.
  • Marked similarities with clear cell carcinomas of the kidney and endometrium have been noted by some investigators, raising interesting possibilities regarding novel therapeutic approaches.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Ovarian Neoplasms / etiology
  • [MeSH-minor] Disease Progression. Drug Resistance, Neoplasm. Female. Genetic Predisposition to Disease. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian clear cell adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 1998 Jun 19;128(2):211-8 [9683285.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):124-5 [9744267.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3674-90 [9817290.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5002-8 [9823298.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):223-9 [9826464.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14745-50 [9843960.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(5):438-40 [9863906.001]
  • [Cites] Exp Cell Res. 1999 Jan 10;246(1):1-10 [9882509.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):553-5 [10215439.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):669-77 [10091740.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2318-23 [10344736.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):177-83 [15586238.001]
  • [Cites] Physiology (Bethesda). 2005 Feb;20:54-9 [15653840.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):520-30 [15661246.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):893-7 [15894369.001]
  • [Cites] J Mol Endocrinol. 2005 Aug;35(1):135-44 [16087727.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):878-83 [16174239.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7212-20 [16192605.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1924-30 [16134181.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):427-31 [16112718.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7911-8 [16204010.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):144-50 [16337857.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):83-9 [16258507.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):257-63 [16254685.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8 [16203778.001]
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):434-7 [10563197.001]
  • [Cites] J Med Invest. 1999 Aug;46(3-4):130-40 [10687307.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):83-8 [10883672.001]
  • [Cites] Oncology. 2000 Jun;59(1):50-6 [10895067.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):187-95 [11063642.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):534-40 [11169935.001]
  • [Cites] Int J Gynecol Pathol. 2001 Apr;20(2):133-9 [11293158.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):537-42 [11494033.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1177-89 [11571731.001]
  • [Cites] Anticancer Drugs. 2002 Jun;13(5):511-9 [12045463.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):723-8 [12079522.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Obstet Gynecol. 2002 Dec;100(6):1290-5 [12468176.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):28-31 [12631216.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):318-25 [12648581.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1578-83 [12771925.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1995-2004 [12796361.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):637-43 [13678738.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5299-305 [14614013.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2503-12 [14633622.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):160-6 [14751152.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(2):169-74 [15032274.001]
  • [Cites] Arch Toxicol. 2004 Mar;78(3):147-55 [14551673.001]
  • [Cites] Hum Pathol. 2004 May;35(5):552-9 [15138928.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Hum Pathol. 1970 Mar;1(1):73-98 [4330995.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(20):7785-9 [2429319.001]
  • [Cites] Am J Surg Pathol. 1987 Sep;11(9):661-7 [2443026.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):65-71 [2642454.001]
  • [Cites] Gynecol Oncol. 1989 Mar;32(3):342-9 [2920955.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Obstet Gynecol. 1971 Jun;37(6):860-7 [4378209.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):250-4 [8504995.001]
  • [Cites] Crit Rev Oncog. 1993;4(4):435-49 [8353142.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1):3-11 [8310306.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):224-7 [7812948.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1605-13 [8608551.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • (PMID = 17018684.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 83
  • [Other-IDs] NLM/ PMC2001101
  •  go-up   go-down


59. Miao Y, Cai B, Liu L, Yang Y, Wan X: Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2009 Dec;19(9):1545-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
  • OBJECTIVE: To investigate the genes that were differentially expressed between clear cell carcinoma (CCC) and serous carcinoma (SAC) of the ovary with complementary DNA microarray.
  • The verification of Annexin IV in the cell line and tissues was in accordance with the result of the microarray.
  • CONCLUSIONS: The complementary DNA microarray technique is a feasible way to explore the difference of the gene expression profiling between the 2 types of ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Annexin A4 / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955935.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Matsuura Y, Robertson G, Marsden DE, Kim SN, Gebski V, Hacker NF: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol; 2007 Feb;104(2):406-10
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboembolic complications in patients with clear cell carcinoma of the ovary.
  • OBJECTIVE: The purpose of this study was to define the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with clear cell carcinoma (CCC) of the ovary and to investigate the prognostic factors in such patients.
  • Sixty-six patients (10.3%) with CCC were identified from the data bank, and their data were compared with a matched-control group of 132 patients with non-clear cell epithelial ovarian carcinoma.
  • In a multivariate analysis of patients matched for age and stage, the occurrence of a DVT or the presence of endometriosis was significant predictors of clear cell histology.
  • Within the clear cell group, no particular risk factor for DVT could be identified.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Ovarian Neoplasms / complications. Pulmonary Embolism / etiology. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014897.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Kato N, Sasou S, Teshima S, Motoyama T: Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary. Virchows Arch; 2007 Mar;450(3):273-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary.
  • One of the characteristic microscopic features of ovarian clear cell carcinoma (CCC) is the densely hyaline basement membrane material expanding the stroma.
  • Recent studies have shown that laminin-5 (LN-5), a major component of the epithelial basement membrane, plays a more active role in cell migration or tumor invasion.
  • In the present study, 20 CCCs and 5 borderline clear cell tumors were examined for LN-5 expression immunohistochemically, using an antibody against LN-5 gamma2 chain.
  • All of the 20 CCCs showed a focal or diffuse immunoreactivity with the LN-5 gamma2 chain in the tumor stroma; whereas, borderline clear cell tumors rarely showed a stromal immunoreactivity.
  • In vitro, CCC cell lines showed a significant increase in cell migration over excessive LN-5, and the migration was blocked by an antibody against integrin alpha3.
  • These results indicate that an interaction between CCC cells and extracellularly accumulated LN-5 is responsible for cell migration and the subsequent stromal invasion of CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Laminin / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Antibodies, Blocking / pharmacology. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Movement / drug effects. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Integrin alpha3 / immunology. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235566.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Biomarkers, Tumor; 0 / Integrin alpha3; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


62. Fennessy BG, Sheahan P, Toner M, Timon C: A subcutaneous mandibulotomy approach for a salivary clear cell carcinoma of the retromolar trigone. Ir J Med Sci; 2010 Mar;179(1):147-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subcutaneous mandibulotomy approach for a salivary clear cell carcinoma of the retromolar trigone.
  • OBJECTIVE: We report a novel subcutaneous mandibulotomy approach for the excision of a rare clear cell carcinoma, not otherwise specified (NOS) of the retromolar trigone.
  • METHOD: Case reports and a review of the medical literature concerning clear cell carcinoma and subcutaneous mandibulotomy are discussed.
  • Clear cell carcinoma, NOS is a rare condition, with few reports in the literature.
  • CONCLUSION: This is the first occasion a subcutaneous mandibulotomy approach for an oral tumour has been described in Great Britain and Ireland, the second reported case of clear cell carcinoma originating in the retromolar trigone region and only the fourth case of associated lymph nodal metastases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Mandible / surgery. Mandibular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696176.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 8
  •  go-up   go-down


63. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci; 2007 Oct;98(10):1586-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
  • A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas.
  • To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells.
  • The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
  • [MeSH-major] Adenocarcinoma, Clear Cell / immunology. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mucin-1 / immunology. Ovarian Neoplasms / immunology. Sialic Acids / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711507.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Mucin-1; 0 / Sialic Acids; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H, Kobayashi H: Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep; 2010 May;23(5):1193-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review).
  • Clear cell EOC (cEOC) has a number of clinical features distinguishing it from other EOC because of frequent concurrence of endometriosis and highly chemoresistant nature resulting in a poor prognosis.
  • A systematic search was performed in the electronic databases PubMed and ScienceDirect up to July 2009, combining the keywords, genome-wide, microarray, epithelial ovarian cancer, clear cell carcinoma, oxidative stress, and detoxification, with specific expression profiles of genes.
  • The catalog of cEOC-specificity might be a manifestation of six essential alterations in cell physiology: oxidative stress and detoxification, proteases, signal transduction, adhesion, transcription, and metabolism.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Gene Expression Regulation, Neoplastic. Hepatocyte Nuclear Factor 1-beta / metabolism. Ovarian Neoplasms / metabolism. Oxidative Stress

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372830.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Oxidants; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  • [Number-of-references] 106
  •  go-up   go-down


65. Ray B, New NE, Wedgwood KR: Clear cell carcinoma of exocrine pancreas: a rare tumor with an unusual presentation. Pancreas; 2005 Mar;30(2):184-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of exocrine pancreas: a rare tumor with an unusual presentation.
  • Metastatic clear cell carcinomas are relatively common from primary tumors arising in the kidney, female genital tract, adrenal cortex, and lung, but they rarely occur from primary tumors of the pancreas.
  • We report a case of metastatic pancreatic tumor with marked clear cell changes in a 46-year-old white man presenting with a pseudocyst of the pancreas.
  • The histologic and immunohistochemical test of the excised omental nodule exhibited features consistent with clear cell carcinoma from pancreatic primary.
  • To our knowledge, this is the first report of a metastatic clear cell pancreatic tumor with such an unusual presentation.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Omentum / pathology. Pancreas, Exocrine / pathology. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714142.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Goto A, Nakajima J, Hara K, Niki T, Fukayama M: Lung adenocarcinoma associated with familial adenomatous polyposis. Clear cell carcinoma with beta-catenin accumulation accompanied by atypical adenomatous hyperplasia. Virchows Arch; 2005 Jan;446(1):73-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma associated with familial adenomatous polyposis. Clear cell carcinoma with beta-catenin accumulation accompanied by atypical adenomatous hyperplasia.
  • There had been no malignant transformation in the specimens from his colectomy and duodenectomy, and a current gastrointestinal investigation revealed no evidence of malignancy.
  • Pathological analysis of the lung tumor demonstrated adenocarcinoma with clear cells and a papillary structure, accompanied by tiny tumorous nodules in the background lung parenchyma.
  • Many of the nodules were multifocal adenocarcinoma; however, some of the nodules demonstrated atypical adenomatous hyperplasia (AAH).
  • This is the first case report of a lung adenocarcinoma accompanied by AAH in a FAP patient.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli / complications. Cytoskeletal Proteins / metabolism. Lung Neoplasms / pathology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660284.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


67. Kajiyama H, Shibata K, Suzuki S, Ino K, Yamamoto E, Mizuno K, Sakakibara K, Matsuzawa K, Takeda A, Kinoshita Y, Kawai M, Nagasaka T, Nawa A, Kikkawa F: Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol; 2008 Dec;111(3):523-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?
  • BACKGROUND: In epithelial ovarian cancer (EOC), fertility-sparing surgery (FSS) has mainly been chosen for stage IA disease.
  • The purpose of this study was to clarify the clinical outcome of patients with clear-cell carcinoma of the ovary (CCC) who would usually undergo radical surgery.
  • Nine patients were alive and one patient with stage IC(2) died of the disease at a follow-up time of 36.8 months.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Fertility. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538833.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Yamashita R, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Primary clear cell carcinoma of the ureter: a case report]. Nihon Hinyokika Gakkai Zasshi; 2006 Mar;97(3):607-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell carcinoma of the ureter: a case report].
  • The pathological diagnosis was clear cell carcinoma with small foci of conventional urothelial carcinoma of the left ureter (pT3pN0, G3 > G2, INFgamma).
  • This is the first case report of clear cell carcinoma of the ureter in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613164.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • Meanwhile, the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis.
  • There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%, and 28 cases in subgroup B for which the proportion was less or equal to 70%, comparing analysis of median survival time of the counterpart groups.
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


70. Uzochukwu NO, Shrier DA, Lapoint RJ: Clear cell carcinoma of the base of the tongue: MR imaging findings. AJNR Am J Neuroradiol; 2007 Jan;28(1):127-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the base of the tongue: MR imaging findings.
  • Clear cell carcinoma of the base of the tongue is a rare minor salivary gland neoplasm, and to our knowledge, the MR imaging appearance of this entity has not been described.
  • We present the MR imaging findings in such a case and review the differential diagnosis for tongue base masses in an adult.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Magnetic Resonance Imaging. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Deglutition Disorders / etiology. Diagnosis, Differential. Female. Humans. Laryngoscopy. Middle Aged. Tongue / pathology. Tongue / surgery

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213438.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C, Verkooijen HM: Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol; 2008;29(1):57-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas.
  • OBJECTIVES: Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC).
  • We excluded those with papillary serous endometrial carcinoma and uterine sarcomas.
  • RESULTS: CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002).
  • Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9).
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Carcinoma, Endometrioid / surgery. Registries. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386465.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


72. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


73. Kato N, Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology; 2008 May;52(6):682-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression.
  • AIMS: Transcription factor hepatocyte nuclear factor (HNF)-1beta is selectively expressed in clear cell carcinoma (CCC) of the ovary.
  • METHODS AND RESULTS: Three CCC and two serous adenocarcinoma (SA) cell lines were evaluated for expression of OPN by reverse transcriptase-polymerase chain reaction and immunocytochemistry.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Hepatocyte Nuclear Factor 1-beta / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Cell Line, Tumor. Female. Gene Expression. Humans. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393978.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 106441-73-0 / Osteopontin; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


74. Ye XP, Li LQ, Peng T, Xiao KY, Su ZX, Shang LM, Su M, Xu BH: [Diagnosis and treatment of primary clear cell carcinoma of the liver]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):64-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary clear cell carcinoma of the liver].
  • OBJECTIVE: To investigate the clinicopathological features, diagnosis, treatment and prognosis of primary clear cell carcinoma of the liver (PCCCL).
  • CONCLUSION: The clinical characteristics of primary clear cell carcinoma of the liver are similar to that of common hepatocellular carcinoma.
  • It is difficult to be diagnosed preoperatively and final diagnosis depends on pathological examination.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211073.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


75. Ma SK, Zhang HT, Wu LY, Liu LY: [Prognostic analysis of 88 patients with ovarian clear cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):784-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
  • OBJECTIVE: To investigate the clinical characteristics of clear cell carcinoma of the ovary and to compare the survival of the patients treated by three different chemotherapy regimens.
  • METHODS: Between 1984 and 2005, the clinical data of 88 surgically treated patients with clear cell carcinoma of the ovary were retrospectively analyzed.
  • The 3- and 5-year survival of the patients with optimal (residual disease less than 2 cm) was 36.7% and 23.1% vs. 22.2% and 0 in those with suboptimal cytoreduction (P < 0.05), it was 46.8% and 38.8% in the patients with elevated CA125 vs. 46.7% and 43.5% in those with normal one (P > 0.05).
  • CONCLUSION: Our data show that ovarian clear cell cancer patient have a poor response to CAP/CP and may have a better response to TC/TP, especially to CPT-11 plus MMC.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms. Ovariectomy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


76. Kato N, Tamura G, Motoyama T: Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch; 2008 Feb;452(2):175-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary.
  • Expression of hepatocyte nuclear factor-1beta (HNF-1beta) is significantly up-regulated in ovarian clear cell carcinoma (CCC).
  • In 2 CCC cell lines, hypomethylation of HNF-1beta CpG island strongly correlated with HNF-1beta expression, at both the mRNA and protein levels.
  • In archival surgical specimens, 20 of 20 CCCs were immunohistochemically positive for HNF-1beta, whereas none of 20 serous adenocarcinomas (SAs) or 12 normal ovaries were positive for it.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. CpG Islands / genetics. DNA Methylation. Hepatocyte Nuclear Factor 1-beta / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Ovary / metabolism. RNA, Messenger / metabolism. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066692.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


77. Hu YJ, Ip PP, Chan KK, Tam KF, Ngan HY: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor. Int J Gynecol Pathol; 2010 Nov;29(6):539-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor.
  • Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare.
  • In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation.
  • To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier.
  • Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG.
  • Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking.
  • Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively.
  • This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis.
  • Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Choriocarcinoma, Non-gestational / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881859.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Kim A, Serada S, Enomoto T, Naka T: Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets; 2010 Sep;14(9):963-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
  • Among the four major histological subtypes of EOC, clear cell carcinoma (CCC) of the ovary is highly resistant to platinum-based chemotherapy and is consequently associated with poor patient prognosis in advanced stages.
  • TAKE HOME MESSAGE: Annexin A4 enhances cancer cell chemoresistance and is overexpressed in tumors of patients with ovarian CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Annexin A4 / metabolism. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Disease Progression. Drug Delivery Systems. Drug Resistance, Neoplasm. Female. Gene Expression Regulation, Neoplastic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673185.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Antineoplastic Agents
  •  go-up   go-down


79. Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2009 Apr;19(3):471-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary.
  • PROBLEM: Clear cell carcinoma (CCC) of the ovary has a number of features distinguishing it from other epithelial ovarian carcinomas (EOC) because of its characteristic histology and biology, frequent concurrence with endometriotic lesion, and highly chemoresistant nature resulting in an extremely poor prognosis.
  • RESULTS: Recent studies based on genome-wide expression analysis technology have noted specific expression of hepatocyte nuclear factor-1beta (HNF-1beta) in endometriosis and CCC, suggesting that early differentiation into the clear cell lineage takes place in the endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Hepatocyte Nuclear Factor 1-beta / metabolism. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407577.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  • [Number-of-references] 132
  •  go-up   go-down


80. Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep; 2006 Dec;16(6):1301-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary has distinct characteristics showing resistance to conventional platinum-based regimen.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage. Platinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089053.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Platinum Compounds; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


81. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis. Arch Gynecol Obstet; 2008 Dec;278(6):569-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis.
  • OBJECTIVE: Ovarian surface epithelial tumors rarely have heterologous elements including bone or cartilage that may appear histologically benign or malignant.
  • CASE: We report a clear cell carcinoma of the bilateral ovary showing chondromatous differentiation in a 56-year-old woman.
  • Histopathologic study of the specimen showed clear cell carcinoma with many small foci of chondromatous differentiation.
  • Immunohistochemical studies demonstrated positivity for S-100 confirming the diagnosis.
  • The patient was alive with disease on chemotherapy for 16 months.
  • CONCLUSION: A rare case of benign appearing chondromatous differentiation in an ovarian clear cell carcinoma of the ovary is described, and the significance of this finding is discussed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Chondroma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation / physiology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343935.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ, Ruba S: Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol; 2008 Oct;27(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of clear cell carcinoma of the ovary.
  • Our impression that primary clear cell carcinoma (CCC) causes disproportionate diagnostic difficulty led us to review the intraoperative and final histopathologic reports from a consecutive series of 44 CCC that were subject to frozen-section assessment and to compare the results with a similar number of primary serous and endometrioid carcinomas.
  • Review of the diagnostic reports showed that CCC was less frequently specifically identified than serous or endometrioid carcinomas on frozen section (44% cases compared with 55% and 65%, respectively), although the differences were not statistically significant.
  • Difficulties in distinguishing primary ovarian carcinoma from tumors metastatic to the ovary occurred in a minority of cases of all histologic subtypes, but was slightly more frequent in CCC.
  • Review of the frozen-section slides from the CCC with discrepant intraoperative diagnoses showed features suggestive or indicative of the correct diagnosis in 7 (39%) of 18 cases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Female. Frozen Sections. Histocytochemistry. Humans. Intraoperative Care / methods. Pathology, Surgical. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753976.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Umezu T, Shibata K, Kajiyama H, Yamamoto E, Nawa A, Kikkawa F: Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J Clin Pathol; 2010 Nov;63(11):962-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
  • BACKGROUND: Glypican-3 (GPC3), a membrane-bound heparan sulphate proteoglycan, may play a role in promoting cancer cell growth and differentiation.
  • Recent studies reported that GPC3 is overexpressed in clear cell carcinoma (CCC) of the ovary, and not other ovarian histotypes.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Glypicans / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Bridged Compounds / therapeutic use. Cell Proliferation. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Prognosis. Survival Analysis. Taxoids / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20972242.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / GPC3 protein, human; 0 / Glypicans; 0 / Neoplasm Proteins; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


84. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG: Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med; 2007 Aug;131(8):1290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
  • CONTEXT: The separation of chromophobe renal cell carcinoma, oncocytoma, and clear cell renal cell carcinoma using light microscopy remains problematic in some cases.
  • OBJECTIVE: To determine a practical immunohistochemical panel for the differential diagnosis of chromophobe carcinoma.
  • DESIGN: Vimentin, glutathione S-transferase alpha (GST-alpha), CD10, CD117, cytokeratin (CK) 7, and epithelial cell adhesion molecule (EpCAM) were investigated in 22 cases of chromophobe carcinoma, 17 cases of oncocytoma, and 45 cases of clear cell carcinoma.
  • RESULTS: Vimentin and GST-alpha expression were exclusively observed in clear cell carcinoma.
  • CD10 staining was more frequently detected in clear cell carcinoma (91%) than in chromophobe carcinoma (45%) and oncocytoma (29%).
  • CD117 was strongly expressed in chromophobe carcinoma (82%) and oncocytoma (100%), whereas none of the cases of clear cell carcinomas were immunoreactive.
  • Cytokeratin 7 was positive in 18 (86%) of 22 cases of chromophobe carcinoma, whereas all oncocytomas were negative for CK7.
  • EpCAM protein was expressed in all 22 cases of chromophobe carcinoma in more than 90% of cells, whereas all EpCAM-positive oncocytomas (5/17; 29%) displayed positivity in single cells or small cell clusters.
  • CONCLUSIONS: Using the combination of 3 markers (vimentin, GST-alpha, and EpCAM), we achieved 100% sensitivity and 100% specificity for the differential diagnosis of chromophobe carcinoma, oncocytoma, and clear cell carcinoma.
  • The pattern of "vimentin(-)/GST-alpha(-)" effectively excluded clear cell carcinoma, and homogeneous EpCAM expression confirmed the diagnosis of chromophobe carcinoma rather than oncocytoma.
  • CD117 and CK7 were also useful markers and could be used as second-line markers for the differential diagnosis, with high specificity (100%) and high sensitivity (90% and 86%, respectively).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Immunoenzyme Techniques / methods. Kidney Neoplasms / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Predictive Value of Tests


85. Dardick I, Leong I: Clear cell carcinoma: review of its histomorphogenesis and classification as a squamous cell lesion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep;108(3):399-405
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma: review of its histomorphogenesis and classification as a squamous cell lesion.
  • In current classification schemes, clear cell carcinoma-including both the hyalinized and nonhyalinized variety--is now an accepted subtype of malignant salivary gland tumors.
  • This review summarizes and illustrates the histologic, ultrastructural, and immunohistochemical evidence for the underlying squamous cell nature of clear cell carcinoma.
  • Squamous cell differentiation is not an uncommon feature of nonneoplastic and neoplastic lesions of the salivary glands.
  • Clear cell carcinoma needs to be added to this list as a unique but specific variety of clear cell squamous carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Epithelial Cells / pathology. Epithelial Cells / ultrastructure. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570692.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


86. Suzuki H, Katoh A, Udaka T, Shiomori T, Fujimura T, Fujimura K, Kitamura T: Hyalinizing clear cell carcinoma arising from the base of the tongue. Acta Otolaryngol; 2006 Jun;126(6):653-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing clear cell carcinoma arising from the base of the tongue.
  • Hyalinizing clear cell carcinoma is a low-grade indolent and rare salivary gland tumor originally described by Milchgrub et al. in 1994.
  • The tumor was histopathologically diagnosed as hyalinizing clear cell carcinoma of the minor salivary gland.
  • The patient is currently free from disease 21 months after surgery.
  • The pathology, clinical characteristics, and treatment of hyalinizing clear cell carcinoma are bibliographically reviewed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Hyalin. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laryngoscopy. Magnetic Resonance Imaging. Neck Dissection. Stromal Cells / pathology. Tomography, X-Ray Computed. Tongue / pathology. Tongue / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720452.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


87. Eloy C, Lopes JM, Faria G, Moreira H, Brandão A, Silva T, Carneiro F: Clear cell change in colonic polyps. Int J Surg Pathol; 2009 Dec;17(6):438-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic polyps.
  • In this study, the pathogenesis of clear cell change in colorectal epithelial lesions was studied.
  • A total of 4 cases of clear cell change (1 hyperplasic polyp and 3 adenomas) were characterized using histochemistry, immunohistochemistry, and electron microscopy.
  • In all, 1 adenoma with clear cell dysplastic glands progressed to adenocarcinoma without clear cell change.
  • Clear cell cytoplasmatic vacuoles were negative for glycogen and mucins (MUC 2, MUC 5AC).
  • Ki-67 LI in clear cell adenoma components was lower than in common adenoma components of the same dysplasia grades (while p53 and beta-catenin were similarly expressed).
  • Ultrastructural features of clear cell change showed features of lipid-like material.
  • Clear cell change is found in hyperplastic and neoplastic lesions of the colon and is not due to the accumulation of glycogen or mucins.
  • A degenerative nature of clear cell change is suggested by the demonstration of lipid-like material in the vacuoles of clear cells.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Intestinal Polyps / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Humans. Hyperplasia. Immunoenzyme Techniques. In Vitro Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18611940.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


88. Kajiyama H, Hosono S, Terauchi M, Shibata K, Ino K, Yamamoto E, Nomura S, Nawa A, Kikkawa F: Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology; 2006;71(5-6):394-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary.
  • We examined the distribution and expression of this molecule in clear cell carcinoma of the ovary (CCC) to elucidate their clinical significance.
  • RESULTS: In the 27 carcinomas, negative Twist immunoexpression was observed in 14 cases (51.9%), and positive immunoexpression in 13 (48.1%).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / diagnosis. Twist Transcription Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Disease Progression. Disease-Free Survival. Female. Humans. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17690559.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Twist Transcription Factor
  •  go-up   go-down


89. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
  • BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


90. Chew I, Soslow RA, Park KJ: Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma. Int J Gynecol Pathol; 2009 Sep;28(5):442-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
  • The effects of chemotherapy on the histologic features of the tumor have not been well described for ovarian carcinoma, especially related to changes that significantly alter the appearance of the tumor.
  • In this study, we describe a case of ovarian serous carcinoma status-post neoadjuvant chemotherapy that showed exuberant clear cell/foamy change.
  • This unusual morphology raised the possibility of a mixed epithelial carcinoma or a secondary malignancy.
  • Immunohistochemical stains were performed to help distinguish whether the tumor was a serous carcinoma with chemotherapy-induced clear cell change or a distinct clear cell carcinoma of ovarian or extraovarian origin.
  • The clear cell and conventional serous components showed diffuse positivity for CK7, CA125, and ER; however, only the clear cell component was positive for hepatocyte nuclear factor-1beta and only the conventional serous component was positive for WT1.
  • Although there was a slight discrepancy in the staining patterns, given the lack of other typical histologic features of clear cell carcinoma, the unusual clear cell morphology was most likely the result of chemotherapy-induced changes.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / pathology. Neoadjuvant Therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Diagnosis, Differential. Female. Humans. Hypercholesterolemia / complications. Hypertension / complications. Immunohistochemistry. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696613.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


91. Suzuki H, Yamauchi G, Hashimoto K: Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar;103(3):e36-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study.
  • Clear cell carcinoma is a rare neoplasm that arises in salivary glands.
  • Initial clinical diagnosis was squamous cell carcinoma based on this erythroplakial lesion.
  • This report examined the immunohistochemical characteristics of clear cell carcinoma, minor salivary gland, and reviewed the existing literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Gingival Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321437.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


92. Lester FC, Farmer DL, Rabban JT, Chen LM: Radical trachelectomy for clear cell carcinoma of the cervix in a 6-year old: a case report, review, and description of the surgical technique. J Pediatr Surg; 2010 Aug;45(8):E1-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical trachelectomy for clear cell carcinoma of the cervix in a 6-year old: a case report, review, and description of the surgical technique.
  • Clear cell carcinoma is a rare pediatric cervical cancer, seen primarily in the setting of in utero diethylstilbesterol exposure.
  • Historically, this type of cancer has been treated with radical hysterectomy and lymph-node dissection, rendering patients incapable of carrying a pregnancy in the future.
  • We describe a young patient with clear cell carcinoma of the cervix who, through a multidisciplinary collaboration, was managed by a fertility-sparing alternative surgical approach--a radical trachelectomy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Fertility / physiology. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713196.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


93. Umezu T, Shibata K, Shimaoka M, Kajiyama H, Yamamoto E, Ino K, Nawa A, Senga T, Kikkawa F: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Cancer Sci; 2010 Jan;101(1):143-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
  • Glypican-3 (GPC3) is a heparan sulfate proteoglycan that is bound to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor, and glypicans can regulate the activity of a wide variety of growth and survival factors.
  • We report here that GPC3 was expressed in clear cell carcinoma of the ovary, and not in other carcinomas.
  • To evaluate the phenotype and potential preclinical relevance, we generated an ovarian cancer cell line stably transfected with plasmids encompassing shRNA targeting GPC3.
  • We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.
  • These results indicate that increased GPC3 expression in a clear cell carcinoma cell line may play a protective role against apoptosis, and so the downregulation of GPC3 may be a potential target to increase sensitivity to paclitaxel-induced apoptosis in clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Glypicans / antagonists & inhibitors. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacology
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Female. Gene Silencing. Humans. Mice. Molecular Sequence Data

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860840.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glypicans; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


94. Skírnisdóttir I, Seidal T, Karlsson MG, Sorbe B: Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol; 2005 Jan;26(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
  • Clear cell carcinoma of the ovary is considered to be a specific subtype among the epithelial ovarian malignancies.
  • To characterize clear cell carcinomas in early FIGO stages (I-II) with regard to clinical and biological properties, a retrospective study was performed to compare these tumors with other histological subtypes.
  • From a complete series of 226 patients with epithelial ovarian carcinomas in FIGO stages I-II, 28 patients with clear cell carcinomas were selected and the clinical and biological characteristics of these tumors were compared with the remaining non-clear cell carcinomas.
  • Clear cell carcinomas stained negative for p53 significantly more often than other histological subtypes.
  • Positive EGFR staining was seen more frequently in serous carcinomas than in the clear cell carcinomas.
  • Aneuploid DNA status was seen more frequently in clear cell carcinomas than in other histological subtypes and tetraploid tumors made up 50% of the non-diploid tumors.
  • Clear cell tumors were frequently (64%) found in FIGO stages IC and IIC and this was more common than for non-clear cell tumors.
  • No difference was found in the rate of tumor recurrences or survival for patients with clear cell and non-clear cell carcinomas.
  • Clear cell carcinomas of the ovary should be regarded as a separate entity among the epithelial ovarian carcinomas and they differ with regard to both clinical and biological characteristics when compared with non-clear cell tumors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Ovarian Neoplasms / diagnosis


95. Takano M, Sugiyama T, Yaegashi N, Sagae S, Kuzuya K, Udagawa Y, Tsuda H, Suzuki M, Kigawa J, Goto T, Tsuda H, Moriya T, Kikuchi Y: Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer; 2010 Dec;20(9):1506-10
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
  • INTRODUCTION: Ovarian clear cell carcinoma (CCC) is regarded as grade 3 tumor, and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines recommend adjuvant chemotherapy for the tumor even at stage IA.
  • METHODS: Clear cell carcinoma cases treated at collaborating institutions during the period 1992-2005 were retrospectively identified.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Ovarian Neoplasms / drug therapy. Ovary / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119366.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Takami M, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Sakamoto H, Yamamoto T: [A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel]. Gan To Kagaku Ryoho; 2007 Mar;34(3):457-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel].
  • Clear cell carcinoma of the endometrium is a very rare and highly malignant neoplasm that accounts for less than 5% of endometrial carcinoma.
  • Survival of patients in the advanced stage is poor, and the treatment of choice is not clear.
  • We report the case of a 62-year-old woman who had Stage IVb advanced clear cell carcinoma of the endometrium with multiple lung metastases.
  • The current case suggests that combination CBDCA plus weekly PTX is effective against advanced clear cell carcinoma of the endometrium.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


97. Vera-Alvarez J, García-Prats MD, Marigil-Gómez M, Abascal-Agorreta M, López-López JI, Ramón-Cajal JM: Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report. Acta Cytol; 2007 Jan-Feb;51(1):107-12
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report.
  • BACKGROUND: Clear cell carcinoma of the ovary (CCC) is a rare variety of ovarian cancer.
  • Peritoneal fluid cytology revealed papillary clusters of cells with clear cytoplasm and extracellular hyaline material generally without neoplastic cells.
  • The tumor was excised, and the histologic sections confirmed the cytologic diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Ascites / etiology. Ascites / pathology. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328509.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Suzuki S, Kajiyama H, Shibata K, Ino K, Nawa A, Sakakibara K, Matsuzawa K, Takeda A, Kinoshita Y, Kawai M, Nagasaka T, Kikkawa F: Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol; 2008 Jul;19(7):1284-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?
  • BACKGROUND: To estimate the survival impact of systemic retroperitoneal lymphadenectomy in patients diagnosed with International Federation of Gynecology and Obstetrics pTI-IIb clear cell carcinoma of the ovary (CCC).
  • Lymphadenectomy was not associated with improved disease-free and overall survival in all patients (P = 0.353 and P = 0.645, respectively).
  • There was no significant difference in the overall and disease-free survival rates in pTI-IIb CCC patients regardless of the completion of surgical staging lymphadenectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356137.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Drebber U, Ortmann M, Kasper HU, Kern MA, Fischer UM, Nemat AT, Dienes HP: [Clear cell tumor of the lung]. Pathologe; 2005 Sep;26(5):378-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell tumor of the lung].
  • Clear cell tumors of the lung are rare tumors composed of epithelioid HMB45 positive tumor cells.
  • It has been proposed that clear cell tumors generate from perivascular epithelioid cells which are also found in renal angiomyolipoma.
  • Due to its morphologic epithelioid features with clear cytoplasm the distinction from either primary or metastatic clear cell carcinoma is difficult.
  • Usually clinical investigations do not lead to the final diagnosis so that only subsequent histological examination and immunophenotyping can establish the correct tumor classification.
  • In frozen sections a solid trabecular tumor was diagnosed, paraffin histology and immunohistochemistry revealed a clear cell tumor of the lung.
  • The difficulty of the correct diagnosis of the clear cell tumor of the lung in frozen sections is discussed as well as the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735949.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Rust MM, Susa J, Naylor R, Cavuoti D: Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy. Acta Cytol; 2008 Jul-Aug;52(4):475-80
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy.
  • BACKGROUND: Endometriosis is considered a premalignant process whose association with carcinoma is well documented.
  • We discuss a case of clear cell carcinoma with an unusual presentation in that it was located outside the abdominal cavity and was the only lesion noted clinically and radiologically.
  • The histopathologic diagnostic criteria will be reviewed, as will the association of carcinomas with endometriosis.
  • Furthermore, we will review the current literature of extraovarian clear cell carcinoma associated with endometriosis with regard to clinical outcome.
  • The FNA sample was reported as highly atypical cells suspicious for adenocarcinoma.
  • Excision of this mass revealed a clear cell carcinoma in a background of endometriosis.
  • CONCLUSION: Clear cell carcinoma is one of the most prevalent carcinomas associated with endometriosis, whether identified in the ovary or extraovarian site.
  • [MeSH-major] Abdominal Wall / pathology. Carcinoma / etiology. Cicatrix / pathology. Endometriosis / complications. Hysterectomy / adverse effects. Soft Tissue Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702369.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down






Advertisement